Aeterna Selects Treatment Candidate for Primary Hypoparathyroidism

Aeterna Selects Treatment Candidate for Primary Hypoparathyroidism

293920

Aeterna Selects Treatment Candidate for Primary Hypoparathyroidism

Aeterna Zentaris, in collaboration with the University of Sheffield, in the U.K., selected AEZS-150 as its lead candidate for primary hypoparathyroidism and will begin formal preclinical studies to assess its therapeutic potential. Data from this preclinical program may support the future launch of the first clinical trial to test the therapy in adults. AEZS-150 was selected from a list of delayed clearance parathyroid hormone fusion polypeptides (DC-PTHs) developed by the University of Sheffield and licensed…

You must be logged in to read/download the full post.